The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Overview of attention for article published in Nature, August 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#27 of 45,922)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Readers on

mendeley
836 Mendeley
citeulike
5 CiteULike
Title
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Published in
Nature, August 2016
DOI 10.1038/nature19323
Pubmed ID
Authors

Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H. Weinreb, Leslie Williams, Marcel Maier, Robert Dunstan, Stephen Salloway, Tianle Chen, Yan Ling, John O’Gorman, Fang Qian, Mahin Arastu, Mingwei Li, Sowmya Chollate, Melanie S. Brennan, Omar Quintero-Monzon, Robert H. Scannevin, H. Moore Arnold, Thomas Engber, Kenneth Rhodes, James Ferrero, Yaming Hang, Alvydas Mikulskis, Jan Grimm, Christoph Hock, Roger M. Nitsch, Alfred Sandrock, Sevigny, Jeff, Chiao, Ping, Bussière, Thierry, Weinreb, Paul H, Williams, Leslie, Maier, Marcel, Dunstan, Robert, Salloway, Stephen, Chen, Tianle, Ling, Yan, O'Gorman, John, Qian, Fang, Arastu, Mahin, Li, Mingwei, Chollate, Sowmya, Brennan, Melanie S, Quintero-Monzon, Omar, Scannevin, Robert H, Arnold, H Moore, Engber, Thomas, Rhodes, Kenneth, Ferrero, James, Hang, Yaming, Mikulskis, Alvydas, Grimm, Jan, Hock, Christoph, Nitsch, Roger M, Sandrock, Alfred

Abstract

Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.

Twitter Demographics

The data shown below were collected from the profiles of 1,305 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 836 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 16 2%
United Kingdom 11 1%
Germany 5 <1%
Spain 5 <1%
France 4 <1%
Netherlands 4 <1%
Mexico 2 <1%
Brazil 2 <1%
Japan 2 <1%
Other 10 1%
Unknown 775 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 214 26%
Researcher 182 22%
Student > Bachelor 125 15%
Student > Master 93 11%
Other 57 7%
Other 165 20%
Readers by discipline Count As %
Agricultural and Biological Sciences 260 31%
Medicine and Dentistry 163 19%
Neuroscience 121 14%
Biochemistry, Genetics and Molecular Biology 100 12%
Chemistry 57 7%
Other 135 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 3009. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 April 2017.
All research outputs
#68
of 7,599,054 outputs
Outputs from Nature
#27
of 45,922 outputs
Outputs of similar age
#5
of 243,713 outputs
Outputs of similar age from Nature
#2
of 982 outputs
Altmetric has tracked 7,599,054 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 45,922 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 70.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,713 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 982 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.